Coagulation Disorders

  • Rajiv K. Pruthi
  • John A. Heit


Reduced to its simplest form, the vascular system is a series of interconnected biologic conduits filled with fluid moving under pressure. This system is subject to injury and must repair itself in order to avoid exsanguination. This latter function is provided by the hemostatic system. Thus, normal hemostasis is a reparative process and consists of three major mechanisms: (1) vasospasm, which is the main mechanism for controlling bleeding after transection/avulsion injuries of large arteries, arterioles, and veins; (2) platelet plug formation; and (3) the procoagulant system. The procoagulant system consists of the mechanisms by which fluid blood is converted into an insoluble hemostatic thrombus. While inherited or acquired disorders of all three mechanisms can cause clinically abnormal bleeding, this chapter reviews the molecular basis of inherited disorders of the procoagulant system (e. g., hemophilia A and B, von Willebrand disease). Inherited vascular and platelet disorders associated with abnormal bleeding are not discussed here.


Factor Versus Polymerase Chain Reac Factor Viii Gene Single Base Pair Change Ristocetin Cofactor Activity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Soucie JM, et al. The Hemophilia Surveillance System Project Investigators. Am J Hematol. 1998;59:288.PubMedCrossRefGoogle Scholar
  2. 2.
    Antonatakis SE, et al. Factor VIII gene inversions in severe hemophilia A: results of an International Consortium Study. Blood. 1995;86:2206.Google Scholar
  3. 3.
    Bagnall RD, et al. Recurrent inversion breaking intron 1 of the factor VIII gene is a frequent cause of severe hemophilia A. Blood. 2002;99:168.PubMedCrossRefGoogle Scholar
  4. 4.
    Gilles JGG, et al. Factor VIII inhibitors. Thromb Haemost. 1997;78:641.PubMedGoogle Scholar
  5. 5.
    ESHRE Preimplantation Genetic Diagnosis Consortium: data collection III. Hum Reprod. 2002;17:233.CrossRefGoogle Scholar
  6. 6.
    GeneTests: Medical Genetics Information Resource [database online]. Seattle, wA: University of Washington and Children’s Health System, 1993–2003. Updated weekly. available at: Scholar
  7. 7.
    Liu Q, et al. Single tube polymerase chain reaction for rapid diagnosis of the inversion hotspot mutation in hemophilia A. Blood. 1998;92:1458.PubMedGoogle Scholar
  8. 8.
    Higuchi M, Kazazian HH Jr, Kasch L, et al. Molecular characterization of severe hemophilia A suggests that about half the mutations are not within the coding regions and splice junctions of the factor VIII gene. Proc Natl Acad Sci U S A. 1991;88:7405.PubMedCrossRefGoogle Scholar
  9. 9.
    Naylor JA, et al. Detection of three novel mutations in two haemophilia A patients by rapid screening of whole essential region of factor VIII gene. Lancet. 1991;337:635.PubMedCrossRefGoogle Scholar
  10. 10.
    Buzin CH, et al. Scanning by DOVAM-S detects all unique sequence changes in blinded analyses: evidence that the scanning conditions are generic. Biotechniques. 2000;28:746–50.PubMedGoogle Scholar
  11. 11.
    Nichols WC, et al. Mutations in an endoplasmic-Golgi intermediate compartment protein cause combined deficiency of coagulation factor V and VIII. Cell. 1998;93:61.PubMedCrossRefGoogle Scholar
  12. 12.
    Warrier I, et al. Factor IX inhibitors and anaphylaxis in haemophilia B. J Pediatr Hematol Oncol. 1997;19:23.PubMedCrossRefGoogle Scholar
  13. 13.
    Ketterling RP, Bottema CD, Phillips JA 3rd, Sommer SS. Evidence that descendants of three founders constitute about 25% of hemophilia B in the United States. Genomics. 1991;10:1093.PubMedCrossRefGoogle Scholar
  14. 14.
    Sadler JE. Von Willebrand disease. In: Scriver CR, Beaudet AL, Valle D, et al., eds. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York: McGraw-Hill, 2001.Google Scholar
  15. 15.
    Mohlke KL, Purkayastha AA, Westrick RJ, et al. MVWF, a dominant modifier of murine von Willebrand factor, results from altered lineage-specific expression of a glycosyltransferase. Cell. 1999;96:111.PubMedCrossRefGoogle Scholar
  16. 16.
    Mazurier C, Meyer D. Factor VIII binding assay of von Willebrand factor and the diagnosis of type 2N von Willebrand disease-results of an international survey. On behalf of the Subcommittee on Von Willebrand Factor of the Scientific and Standardization Committee of the ISTH. Thromb Haemost. 1996;76:270.PubMedGoogle Scholar
  17. 17.
    Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A. 1993;90:1004–1008.PubMedCrossRefGoogle Scholar
  18. 18.
    Sun X, Evatt B, Griffin JH. Blood coagulation factor Va abnormality associated with resistance to activated protein C in venous thrombophilia. Blood. 1994;83:3120–3125.PubMedGoogle Scholar
  19. 19.
    Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64–67.PubMedCrossRefGoogle Scholar
  20. 20.
    Heit JA, Silverstein MD, Mohr DN, et al. The epidemiology of venous thromboembolism in the community: state of the art. Thromb Haemost. 2001;86:452–463.PubMedGoogle Scholar
  21. 21.
    Heit JA, O’Fallon WM, Petterson TM, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med. 2002;162:1245–1248.PubMedCrossRefGoogle Scholar
  22. 22.
    Press RD, Bauer KA, Kujovich JL, Heit JA. Clinical utility of Factor V Leiden (R506Q) testing for the diagnosis and management of thromboembolic disorders. Arch Pathol Lab Med. 2002;126:1304–1318.PubMedGoogle Scholar
  23. 23.
    Rodeghiero F, Tosetto A. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism. Ann Intern Med. 1999;130:643–650.PubMedGoogle Scholar
  24. 24.
    Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oralcontraceptive users who are carriers of factor V Leiden mutation. Lancet. 1994;344:1453–1457.PubMedCrossRefGoogle Scholar
  25. 25.
    Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 19;88:3698–3703.Google Scholar
  26. 26.
    Gehring NH, Frede U, Neu-Yilik G, et al. Increased efficiency of mRNA 3′ end formation: a new genetic mechanism contributing to hereditary thrombophilia. Nat Genet. 2001;28:389–392.PubMedCrossRefGoogle Scholar
  27. 27.
    Soria JM, almasy L, Souto J, et al. Linkage analysis demonstrates that the prothrombin G20210A mutation jointly influences plasma prothrombin levels and risk of thrombosis. Blood. 2000;95:2780–2785.PubMedGoogle Scholar
  28. 28.
    McGlennen RC, Key NS. Clinical and laboratory management of the prothrombin G20210A mutation. Arch Pathol Lab Med. 2002;126:1319–1325.PubMedGoogle Scholar
  29. 29.
    Key NS, McGlennen RC. Hyperhomocyst(e)inemia and thrombophilia. Arch Pathol Lab Med. 2002;126:1367–1375.PubMedGoogle Scholar
  30. 30.
    Mudd SH, Skoyby F, Levy HL, et al. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet. 1985;37:1–31.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Rajiv K. Pruthi
    • 1
  • John A. Heit
    • 2
  1. 1.Department of Hematology and Internal Medicine, Department of Laboratory Medicine and PathologyMayo Clinic College of MedicineRochesterUSA
  2. 2.Division of HematologyMayo ClinicRochesterUSA

Personalised recommendations